The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina
Open accessAbstract
Background —Unstable angina and non–Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and in combination with heparin in patients with these conditions to select the most promising lamifiban regimen for subsequent evaluation. Methods and Results —At 273 hospitals in 20 countries, 2282 patients were randomly assigned to lamifiban (2×2 factorial design: low-dose [1 μg/min] with and without heparin versus high-dose [5 μg/min] with and without heparin) or to standard therapy (placebo and heparin). All patients received aspirin. The composite primary end point of death or nonfatal myocardial infarction at 30 days occurred in 11.7% of those receiving standard therapy, 10.6% receiving low-dose lamifiban, and 12.0% receiving high-dose lamifiban ( P =0.668). By 6 months, this composite was lowest for those assigned to low-dose lamifiban ( P =0.027) and intermediate for those assigned to high-dose lamifiban ( P =0.450) compared with control (13.7%, 16.4%, and 17.9%, respectively). Compared with control, the combination of high-dose lamifiban and heparin resulted in more intermediate or major bleeding (12.1% versus 5.5%; P =0.002) and a similar rate of ischemic events. Conversely, low-dose lamifiban and heparin yielded similar bleeding rates as in the control group but fewer ischemic events at 6 months (12.6% versus 17.9%; P =0.025). Conclusions —In unstable angina and non–Q-wave infarction, platelet IIb/IIIa antagonism with lamifiban reduces adverse ischemic events at 6 months beyond that of aspirin and heparin therapy. The role of conjunctive heparin remains uncertain but appears more favorable with low-dose IIb/IIIa antagonism. Larger-scale study is needed to more reliably estimate these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
Davies, M. J., & Thomas, A. C. (1985) · Heart · doi:10.1136/hrt.53.4.363 · Cited by 1,985
(1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362401 · Cited by 1,883
Aspirin, Heparin, or Both to Treat Acute Unstable Angina
Théroux, P., Ouimet, H., McCans, J., Latour, J.-G., Joly, P., Lévy, G., Pelletier, E., Juneau, M., Stasiak, J., deGuise, P., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810273191701 · Cited by 1,276
Aspirin, Sulfinpyrazone, or Both in Unstable Angina: Results of a Canadian Multicenter Trial
Cairns, J. A., Gent, M., Singer, J., Finnie, K. J., Froggatt, G. M., Holder, D. A., Jablonsky, G., Kostuk, W. J., Melendez, L. J., Myers, M. G., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511283132201 · Cited by 1,120
The RISC Group (1990) · The Lancet · doi:10.1016/0140-6736(90)92336-g · Cited by 781
A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
(1996) · New England Journal of Medicine · doi:10.1056/nejm199609123351103 · Cited by 660
The restenosis paradigm revisited: An alternative proposal for cellular mechanisms
Schwartz, R. S., Holmes, D. R., & Topol, E. J. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90389-5 · Cited by 563
Topol, E. J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550060055036 · Cited by 399
Cited by
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,510
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
(1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,432
Metadata
- Venue
- Circulation
- Published
- 1998-06-23
- Volume
- 97
- Issue
- 24
- Pages
- 2386-2395
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2207113963
- Cited by
- 386
- References
- 14
- FWCI
- 46.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina. https://app.cochat.ai/papers/10.1161/01.cir.97.24.2386
- The paper
- International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina. (1998). Circulation. https://doi.org/10.1161/01.cir.97.24.2386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.